REVOLUTION, Invivyd’s development program for VYD2311, comprises the DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID ...

CVS Health Corp said on Wednesday it would administer Eli Lilly & Co's experimental antibody treatment to COVID-19 patients in their homes and in long-term care facilities through a U.S.

Nextcure ( ($NXTC) ) has released its Q3 earnings. Here is a breakdown of the information Nextcure presented to its investors. NextCure, Inc. is a ...

The Denmark-based firm said Wednesday that it has agreed to cut the cost of semaglutide, the active ingredient in weight-loss ...

The brain drug developer plans to slash R&D expenses by about 60% in the wake of the FDA surprisingly rejecting its rare disease drug Vyglxia.

After Pfizer agreed to acquire weight-loss drug developer Metsera for $7.3 billion, Novo Nordisk swooped in with an ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for antibody–drug conjugates (ADCs), and Xcellon Biologics, a U.S.-based contract ...

| According to DataM Intelligence AUSTIN, Texas and TOKYO, Oct. 27, 2025 /PRNewswire/ -- The Antibody-Drug Conjugates (ADC) Market Size was valued at around US $11.9 billion in 2024, the market is ...